Company Analysis

MIRA Pharmaceuticals, Inc. (MIRA)

Nasdaq: MIRA · Pharmaceutical Preparations · Miami, FL · filing with the SEC since 2022
Grade4.7
◀ Past 4.3● Present 3.7▶ Future 5.7
6 est.

Who runs MIRA Pharmaceuticals, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Aminov Erez
Chief Executive Officer. First filing Aug 2023, latest Apr 1, 2026, 2 filings in all.
Officers reporting now
2
of 6 people with a filing in the last fifteen months
Directors reporting now
4
17 people on the record since 2023
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Mushak AndriyChief Financial OfficerJun 2026Jun 9, 2026none
Aminov ErezChief Executive OfficerAug 2023Apr 1, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Del Giudice Matthew PauldirectorMar 2024Jun 15, 2026none
Macpherson Edward CloustondirectorMar 2024Jun 15, 2026none
Shekhat Denil NanjidirectorMar 2024Jun 15, 2026none
Whalen Matthew PrattdirectorNov 2024Jun 15, 2026none
Earlier names on the record14, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton MIRA · research, not advice